Tyra
IPO- Headquarters
- Carlsbad, California
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- tyrabio.com
- Total Funding
- $306.0M
- Last Round
- $106.0M Series B
- Rounds
- 2
About
Tyra Biosciences (Nasdaq: TYRA) is a clinical-stage biotechnology company developing next-generation precision medicines targeting FGFR biology to overcome acquired resistance in oncology and genetically defined conditions. The company's proprietary SNÅP platform enables rapid, iterative molecular drug design to predict and preempt genetic alterations that cause resistance to existing therapies. Its lead programs include TYRA-300, a potential first-in-class selective FGFR3 inhibitor, and TYRA-200, an FGFR1/2/3 inhibitor for intrahepatic cholangiocarcinoma.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Biopharmaceutical services company
Specialty pharmaceutical company
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
Global clinical research organization specializing in early-stage clinical trials and bioanalytic...